Aims To test the hypothesis that urate predicts cardiac death after stroke independent of conventional risk factors of atherosclerosis, creatinine and diuretic use.
Introduction
In the first 30 days after a stroke, 90% of deaths are due to the direct effects of the brain lesion or due to complications of immobility resulting from the stroke. However, if the stroke patient survives the initial cerebrovascular event, the most likely cause of death from 6 months onwards is cardiovascular (non-stroke) or sudden death [1] . In current clinical practice, control of the conventional cardiovascular risk factors such as blood pressure, cholesterol, glucose and smoking is usually undertaken after a stroke. An ECG is also performed to exclude overt myocardial ischaemia, atrial fibrillation and left ventricular hypertrophy. In the light of the HOPE study [2] , ramipril might be considered because ramipril appeared to have a beneficial effect on the composite outcome of myocardial infarction, stroke or death from cardiovascular causes. Despite the above, cardiac death is still common in stroke survivors, which increases the need for identifying novel risk factors and novel treatments. Over recent years, there has been renewed debate about the nature of the association between raised serum uric acid concentration and cardiovascular disease [3] . An epidemiological link between elevated serum uric acid and an increased cardiovascular risk has been recognized for many years [4, 5] . However, it has been argued that the relationship between urate and death from cardiovascular disease may be spurious since elevated serum uric acid is associated with many of the risk factors that predispose to cardiovascular disease -for example, hypertension, hyperlipidaemia, diabetes, and male sex. Further, urate can also be raised in patients with renal failure and in patients who are on diuretics -this might account for the link between urate and cardiovascular prognosis. Indeed, studies which performed multivariate analyses to examine whether urate independently predicts poor cardiovascular prognosis have yielded conflicting results [6] [7] [8] [9] . The question which now arises but which has never been addressed is whether urate could predict cardiac death in patients who have survived a stroke. This is an important question to answer since an independent relationship between cardiac death and urate would increase the validity of a large randomized controlled trial to test whether lowering urate with allopurinol would also lower cardiac mortality.
Methods
Three hundred and fifty-four stroke survivors were seen approximately 1 year after their stroke (median 1·0 year (range 0·23-2·0 years)). It was at this follow-up clinic that urate was measured, along with the assessment of the other more conventional risk factors.
Median follow-up time was 2·8 years (up to 5·9 years). The certified cause of death among the patients during the follow-up period was obtained by record linkage with data from the Registrar General in Scotland. Cardiac death was the primary end-point and was defined by the following ICD9 codes: 410.0-414.9, and 429.2. This clearly excluded deaths attributable to a recurrent stroke.
Statistical analysis was performed using SPSS for Windows. Univariate analyses (Cox regression) allowed us to test whether urate was associated with cardiac death. By way of comparison, death from all causes was also considered as an end-point of interest. Relative risks and their 95% confidence interval (CI) of having urate greater than the median were calculated.
Multivariate Cox regression analyses were performed to test if urate predicted cardiac death after adjusting for other well known conventional risk factors i.e. age, sex, glucose, cholesterol and pulse pressure. Pulse pressure was chosen over systolic blood pressure since recent data suggest that the former is a better risk predictor [10] and we could not for statistical reasons enter both variables in our analysis because they are highly interdependent. In addition, some would argue that alcohol intake, aspirin use and the level of disability from the stroke may all be confounding factors. We have thus included all the above factors into a multiple regression model. (All continuous variables were divided into two equal groups for assessment of relative risk i.e. glucose, cholesterol, pulse pressure at the clinic visit and neurological score (a measure of the level of disability); and aspirin use were also entered into the Multivariate Cox Regression model as '0 or 1 variables'; whilst alcohol use was divided into three groups-abstainers, 1-21 units . week 1 and in excess of 21 units per week). Importantly, it is well known that raised urate can be a side-effect of diuretic therapy. Further, urate can be increased in patients with renal failure. Clearly, patients on diuretics may have a greater risk of cardiac death because they are likely to have pre-existing cardiac failure necessitating the use of diuretics in the first place. Renal impairment may also be a confounding variable. We have therefore performed both univariate and multivariate analyses on patients who were not on diuretics at the time they were followed-up at clinic when the urate was measured. Further, creatinine was entered along with the other conventional risk factors (pulse pressure, glucose, cholesterol, age and sex) in the multivariate Cox regression model to test if there was any independent relationship between a high urate and cardiac death. All the variables examined were categorized into two groups (with the median as cut-off) for analyses of relative risks.
Sensitivity and specificity of diagnosing cardiac death within 5 years after the cerebrovascular event were derived from receiver-operator characteristics (ROC) curves. Only patients who had been in the study for long enough to determine their 5 year cardiac survival at the time when linkage to mortality data was completed were included in the sensitivity and specificity analysis. Also, in order to calculate sensitivities and specificities of predicting cardiac death, if a patient died within 5 years of a non-cardiac cause, the patient had inevitably to be excluded from this particular analysis.
Kaplan-Meier survival analysis compared the difference in mortality between patients with urate greater than 0·31 mmol . l 1 and those with urate equal to or below 0·31 mmol . l 1 . A P value of less than 0·05 (derived from log rank test) was regarded as statistically significant.
The study complies with the Declaration of Helsinki. The Tayside Committee on Medical Research Ethics has given approval to the study.
Results
Out of the 354 patients studied, 47 died (13·3%). Nineteen (5·4%) died of a cardiac cause; three died of a non-cardiac vascular cause (0·8%); 17 died of a stroke (4·8%); eight died of other miscellaneous causes (2·3%); 10 cardiac deaths occurred in the 252 patients who were not on diuretics. The baseline characteristics of the patients were summarized in Table 1 .
If serum urate concentration was higher than 0·32 mmol . l 1 , the patient had a significantly higher risk of cardiac death (greater than threefold relative risk), even after adjusting for the conventional risk factors of age, sex, pulse pressure, glucose and cholesterol (Table 2) .
Urate >0·32 mmol . l 1 was still independently associated with cardiac death after adjusting for age, sex, pulse pressure, glucose, cholesterol, aspirin use, alcohol consumption and neurological score. (Adjusted relative risk was 3·2 (95% CI 1·1-9·4, P=0·029).)
To overcome the potential confounding effects of diuretic use, we decided to perform Cox regression analyses on the subset of patients who were not on diuretics at the time when urate was measured. Importantly, we found that a high urate (greater than or equal to median) was associated with an even greater relative risk of cardiac death (8·9 in univariate analysis, P=0·038) (Table 3) . Further, we entered creatinine in addition to the other conventional risk factors (pulse pressure, glucose, cholesterol, age and sex) into a multivariate Cox regression model to test the relationship between urate and cardiac death. A high urate d0·31 mmol . l 1 (median of this cohort) was associated with a 12-fold increase in relative risk of cardiac death even after adjusting for pulse pressure, glucose, cholesterol, age and sex and taking into account of the patient's serum creatinine concentration (Table 4) .
In order to determine the sensitivity and specificity of urate at predicting 5-year cardiac mortality after stroke, a receiver-operator characteristics (ROC) curve was plotted, again using data from the subgroup who were not on diuretics at the time when urate was measured (area 0·701, 95% CI 0·526-0·876; n=66, nine cardiac deaths). Using a cut-off value of 0·31 mmol . l 1 , the test was 78% sensitive, but only 54% specific. However, if the patient's urate was greater than or equal to 0·38 mmol . l 1 , then there would be a high probability of death from a cardiac cause within 5 years of the stroke (specificity=88%) (Table 5(a)). If we did not exclude patients who were on diuretics, there would be 18 cardiac deaths in the cohort of 100 stroke survivors: the receiver-operator characteristics (ROC) curve thus obtained had an area of 0·68, 95% CI 0·55-0·81, P=0·017 (Table 5 (b)). Using a cut-off value of 0·31 mmol . l 1 , the test was 83% sensitive, but only 49% specific. If the patient's urate concentration was greater than or equal to 0·38 mmol . l 1 , then the test was 82% specific at predicting cardiac death within 5 years of the stroke.
The relationship between a urate concentration of greater than 0·31 mmol . l 1 and cardiac death in the unselected cohort of stroke patients was graphically depicted by a Kaplan-Meier survival plot shown in Fig. 1 (log rank P=0·0065) .
Discussion
The principal finding of this paper is that raised serum urate concentration was associated with a statistically significant increase in relative risk of cardiac death even after adjusting for renal function and other conventional risk factors in patients who were not taking diuretics.
When it comes to using serum urate as a prognostic marker one must take note of the confounding influences of diuretic therapy and renal dysfunction, both of which could lead to a spurious relationship between uric acid and mortality. The Framingham study identified diuretic use as the covariate responsible for rendering serum uric acid a statistically non-significant predictor of outcome in a stepwise Cox model [8] . This issue is of course controversial because some of the other large studies relating uric acid positively with mortality did find such a relationship independent of diuretic use [6, 11] . It is for these reasons that we explored in detail the relationship that existed between urate and cardiovascular mortality. In order to clarify the issue, as best we could, we thought that rather than trying to correct for diuretic therapy in a multiple regression model, it would Figure 1 Urate >0·31mmol . l 1 is associated with a significant increased risk of cardiac death in an unselected cohort of stroke survivors.
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be more convincing if we found that uric acid was still related to mortality once we had excluded all patients on diuretic therapy (of any kind) at the time urate was measured. Despite excluding these potential confounding patients, we did still find a significant independent relationship between urate and cardiac death.
Some researchers have suggested that renal dysfunction elevates uric acid and that this may be the reason why uric acid correlates with mortality [12] . Some of the studies that demonstrated a link between urate and poor cardiovascular prognosis did not include creatinine in their multivariate analyses. In our study, creatinine did not predict cardiac death in the subgroup of patients who were not on diuretics. Nevertheless, creatinine was entered into the multivariate model, and urate still remained a significant predictor of cardiac death following stroke.
The thorough critique may also argue that uric acid may be released from skeletal muscle undergoing atrophy. Therefore more disabling strokes may be characterized by higher serum uric acid levels. Clearly the level of disability from the stroke may be related to death. The neurological score is a measure of the level of disability from the stroke. However, we found that urate appeared to be associated with cardiac death independent of the neurological score too.
The question that remains is why urate appears to be independently associated with cardiac death after stroke. Is urate per se harmful to the coronary vessels? Or could it be that uric acid is a marker for some other biological process that accelerates death?
Xanthine oxidase activity [13] is increased in vivo under ischaemic conditions. In the human coronary circulation, hypoxia, caused by transient coronary artery occlusion during angioplasty, leads to an increase in the local circulating concentration of uric acid [14] . Therefore, raised serum urate may act as a marker of underlying myocardial ischaemia.
A link between elevated serum urate and cardiovascular disease may arise through its non-causal relationship with insulin resistance syndromes, where cardiovascular risk is mediated by other factors. Insulin has a physiological action on renal tubules, causing reduced sodium and uric acid clearance [15] . We did not measure insulin or C-peptide levels, but chose to enter glucose and pulse pressure into the multivariate model. We found that urate was able to predict cardiac death independent of both pulse pressure and glucose. Interestingly, it appears that raised serum uric acid may predict subsequent development of diabetes [16] and hypertension [17] . There is thus increasing data suggesting that uric acid could be independently associated with cardiovascular disease. One of the possible mechanisms whereby hyperuricaemia causes vascular disease is via endothelial dysfunction. Evidence for this hypothesis comes from four different types of data. Firstly, exogenous uric acid caused endothelial dysfunction when infused directly into the human brachial artery [18] . Secondly, endogenous uric acid levels correlated with endothelial dysfunction in populations [19] . Thirdly, the biological plausibility of the two above findings is increased by the following observations: uric acid was found to promote low-density lipoprotein (LDL) oxidation in vitro [20] , a key step in the progression of atherosclerosis. In addition, uric acid could stimulate granulocyte adherence to the endothelium [21] . A consistent relationship has also been noted between elevated serum uric acid concentration and circulating inflammatory markers [22] [23] [24] . Moreover, urate could be phagocytosed by endothelial cells [25] . Further, Waring et al. pointed out in an interesting review which discussed uric acid as a risk factor for cardiovascular disease [26] , that uric acid could even traverse dysfunctional endothelial cells and accumulate as crystals within atherosclerotic plaques [27] . Fourthly, three studies already showed that xanthine oxidase inhibition normalized endothelial dysfunction [28] [29] [30] . However, allopurinol produces other non-urate effects which might be beneficial, i.e. allopurinol might be beneficial because of two distinct effects: it reduces uric acid per se and it also reduces oxidative stress because an ancillary property of xanthine oxidase is to make superoxide anions which normally degrade vascular nitric oxide [28] [29] [30] . The fact that urate predicted cardiac mortality and the fact that allopurinol improved endothelial dysfunction made allopurinol an attractive possibility distinctly worthy of further investigation. There is already evidence that intravenous allopurinol improved cardiac function post coronary bypass surgery [13] . It would be interesting to know if oral allopurinol can reduce cardiac deaths in stroke survivors with urate levels greater than or equal to 0·38 mmol . l 1 (the cut-off value that predicted cardiac death with >80% specificity in the present study).
Limitations of our study: whilst our study found urate was associated with cardiac death independent of many potential confounding variables, some dietary factors could have affected urate levels. Although we have entered alcohol into a multivariate model and shown that urate was associated with cardiac death independent of alcohol consumption, our study did not take into account the possible effects of other dietary factors (e.g. vegetarian diet) [31] on urate levels, and further studies will be necessary to determine if control of other dietary factors may not only reduce urate levels, but also alter cardiac survival.
Conclusions
In conclusion, raised serum urate concentration following stroke predicted subsequent cardiac death independent of conventional risk factors and of renal function or diuretic use. If urate was greater than or equal to 0·38 mmol . l 1 in a patient who was not on diuretics, the specificity of predicting cardiac death in that patient within 5 years after stroke was 88%. Further prospective studies are now required to address two issues. Firstly, in stroke survivors with asymptomatic hyperuricaemia, is allopurinol effective in the prevention of cardiac death? Alternatively, urate may be a marker for hidden but treatable cardiac disease: therefore, the second issue is what precise cardiac abnormalities are overrepresented in stroke survivors with a high urate? In this context, urate may simply be a convenient and easy marker to identify patients with hidden but lethal cardiac disease.
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